Cost and healthcare utilization of methicillin-resistant Staphylococcus aureus bacteremia estimated from linked antimicrobial resistance surveillance and hospital claims data in Japan
Abstract Objective: To compare the incremental costs and healthcare utilization of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia with those of methicillin-susceptible S. aureus (MSSA) bacteremia. Design: Retrospective cohort study using data from April 2014 to March 2015. Setti...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Cambridge University Press
2022-01-01
|
| Series: | Antimicrobial Stewardship & Healthcare Epidemiology |
| Online Access: | https://www.cambridge.org/core/product/identifier/S2732494X22002807/type/journal_article |
| _version_ | 1827995833876873216 |
|---|---|
| author | Tomokazu Shoji Ryusei Muto Haruhisa Fukuda Yuichi Muraki Keishi Kawata Manabu Akazawa |
| author_facet | Tomokazu Shoji Ryusei Muto Haruhisa Fukuda Yuichi Muraki Keishi Kawata Manabu Akazawa |
| author_sort | Tomokazu Shoji |
| collection | DOAJ |
| description |
Abstract
Objective:
To compare the incremental costs and healthcare utilization of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia with those of methicillin-susceptible S. aureus (MSSA) bacteremia.
Design:
Retrospective cohort study using data from April 2014 to March 2015.
Setting:
Antimicrobial resistance surveillance and hospital claims data from 16 Japanese hospitals.
Patients:
The study included 73 patients with S. aureus bacteremia: 23 with MRSA and 50 with MSSA.
Methods:
MRSA bacteremia was identified using blood cultures and drug-susceptibility tests. MRSA- and MSSA-related medical practices were evaluated. The costs were calculated and compared. All the medical costs were classified into empirical and definitive therapy periods and expressed in Japanese yen (JPY, 1 USD = 106 JPY). Additionally, costs at aggressive and passive bacterial test-performing facilities were compared.
Results:
No significant differences existed in MRSA-related resource use per patient episode between MRSA and MSSA bacteremia during empirical therapy. However, during definitive therapy, in MRSA bacteremia compared with MSSA bacteremia, this difference was higher. The average MRSA-related costs of empirical therapy for MRSA and MSSA were 13,380 and 9,140 JPY (126 and 86 USD) per patient, and for definitive therapy, they were 69,810 and 29,510 JPY (659 and 278 USD) per patient, respectively. No significant differences were noted. Conversely, the average examination costs during definitive therapy differed significantly: 9,740 vs 3,850 JPY (92 vs 36 USD), respectively (P = .0294). Furthermore, the incremental costs in aggressive facilities were lower for the definitive therapy period than those in passive facilities.
Conclusions:
In the definitive therapy period, MRSA bacteremia had higher incremental costs and greater use of healthcare resources. In addition, the incremental costs in aggressive facilities were lower than those in passive facilities.
|
| first_indexed | 2024-04-10T05:02:44Z |
| format | Article |
| id | doaj.art-a277fbcbb67648498ef7abecf29ff6eb |
| institution | Directory Open Access Journal |
| issn | 2732-494X |
| language | English |
| last_indexed | 2024-04-10T05:02:44Z |
| publishDate | 2022-01-01 |
| publisher | Cambridge University Press |
| record_format | Article |
| series | Antimicrobial Stewardship & Healthcare Epidemiology |
| spelling | doaj.art-a277fbcbb67648498ef7abecf29ff6eb2023-03-09T12:28:16ZengCambridge University PressAntimicrobial Stewardship & Healthcare Epidemiology2732-494X2022-01-01210.1017/ash.2022.280Cost and healthcare utilization of methicillin-resistant Staphylococcus aureus bacteremia estimated from linked antimicrobial resistance surveillance and hospital claims data in JapanTomokazu Shoji0https://orcid.org/0000-0003-0639-5675Ryusei Muto1Haruhisa Fukuda2https://orcid.org/0000-0003-1120-1548Yuichi Muraki3https://orcid.org/0000-0001-6951-5676Keishi Kawata4Manabu Akazawa5https://orcid.org/0000-0002-4112-6035Department of Public Health and Epidemiology, Meiji Pharmaceutical University, Tokyo, Japan Department of Pharmacy, University of Yamanashi Hospital, Yamanashi, JapanDepartment of Public Health and Epidemiology, Meiji Pharmaceutical University, Tokyo, JapanDepartment of Health Care Administration and Management, Graduate School of Medical Sciences Kyushu University, Fukuoka, JapanDepartment of Clinical Pharmacoepidemiology, Kyoto Pharmaceutical University, Kyoto JapanDepartment of Pharmacy, University of Yamanashi Hospital, Yamanashi, JapanDepartment of Public Health and Epidemiology, Meiji Pharmaceutical University, Tokyo, Japan Abstract Objective: To compare the incremental costs and healthcare utilization of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia with those of methicillin-susceptible S. aureus (MSSA) bacteremia. Design: Retrospective cohort study using data from April 2014 to March 2015. Setting: Antimicrobial resistance surveillance and hospital claims data from 16 Japanese hospitals. Patients: The study included 73 patients with S. aureus bacteremia: 23 with MRSA and 50 with MSSA. Methods: MRSA bacteremia was identified using blood cultures and drug-susceptibility tests. MRSA- and MSSA-related medical practices were evaluated. The costs were calculated and compared. All the medical costs were classified into empirical and definitive therapy periods and expressed in Japanese yen (JPY, 1 USD = 106 JPY). Additionally, costs at aggressive and passive bacterial test-performing facilities were compared. Results: No significant differences existed in MRSA-related resource use per patient episode between MRSA and MSSA bacteremia during empirical therapy. However, during definitive therapy, in MRSA bacteremia compared with MSSA bacteremia, this difference was higher. The average MRSA-related costs of empirical therapy for MRSA and MSSA were 13,380 and 9,140 JPY (126 and 86 USD) per patient, and for definitive therapy, they were 69,810 and 29,510 JPY (659 and 278 USD) per patient, respectively. No significant differences were noted. Conversely, the average examination costs during definitive therapy differed significantly: 9,740 vs 3,850 JPY (92 vs 36 USD), respectively (P = .0294). Furthermore, the incremental costs in aggressive facilities were lower for the definitive therapy period than those in passive facilities. Conclusions: In the definitive therapy period, MRSA bacteremia had higher incremental costs and greater use of healthcare resources. In addition, the incremental costs in aggressive facilities were lower than those in passive facilities. https://www.cambridge.org/core/product/identifier/S2732494X22002807/type/journal_article |
| spellingShingle | Tomokazu Shoji Ryusei Muto Haruhisa Fukuda Yuichi Muraki Keishi Kawata Manabu Akazawa Cost and healthcare utilization of methicillin-resistant Staphylococcus aureus bacteremia estimated from linked antimicrobial resistance surveillance and hospital claims data in Japan Antimicrobial Stewardship & Healthcare Epidemiology |
| title | Cost and healthcare utilization of methicillin-resistant Staphylococcus aureus bacteremia estimated from linked antimicrobial resistance surveillance and hospital claims data in Japan |
| title_full | Cost and healthcare utilization of methicillin-resistant Staphylococcus aureus bacteremia estimated from linked antimicrobial resistance surveillance and hospital claims data in Japan |
| title_fullStr | Cost and healthcare utilization of methicillin-resistant Staphylococcus aureus bacteremia estimated from linked antimicrobial resistance surveillance and hospital claims data in Japan |
| title_full_unstemmed | Cost and healthcare utilization of methicillin-resistant Staphylococcus aureus bacteremia estimated from linked antimicrobial resistance surveillance and hospital claims data in Japan |
| title_short | Cost and healthcare utilization of methicillin-resistant Staphylococcus aureus bacteremia estimated from linked antimicrobial resistance surveillance and hospital claims data in Japan |
| title_sort | cost and healthcare utilization of methicillin resistant staphylococcus aureus bacteremia estimated from linked antimicrobial resistance surveillance and hospital claims data in japan |
| url | https://www.cambridge.org/core/product/identifier/S2732494X22002807/type/journal_article |
| work_keys_str_mv | AT tomokazushoji costandhealthcareutilizationofmethicillinresistantstaphylococcusaureusbacteremiaestimatedfromlinkedantimicrobialresistancesurveillanceandhospitalclaimsdatainjapan AT ryuseimuto costandhealthcareutilizationofmethicillinresistantstaphylococcusaureusbacteremiaestimatedfromlinkedantimicrobialresistancesurveillanceandhospitalclaimsdatainjapan AT haruhisafukuda costandhealthcareutilizationofmethicillinresistantstaphylococcusaureusbacteremiaestimatedfromlinkedantimicrobialresistancesurveillanceandhospitalclaimsdatainjapan AT yuichimuraki costandhealthcareutilizationofmethicillinresistantstaphylococcusaureusbacteremiaestimatedfromlinkedantimicrobialresistancesurveillanceandhospitalclaimsdatainjapan AT keishikawata costandhealthcareutilizationofmethicillinresistantstaphylococcusaureusbacteremiaestimatedfromlinkedantimicrobialresistancesurveillanceandhospitalclaimsdatainjapan AT manabuakazawa costandhealthcareutilizationofmethicillinresistantstaphylococcusaureusbacteremiaestimatedfromlinkedantimicrobialresistancesurveillanceandhospitalclaimsdatainjapan |